Performance of serum HBcrAg in chronic hepatitis B patients with 8-year nucleos(t)ide analogs therapy - 18/06/19
, Chuan-Min Tao b, Juan Liao a, b, Tao-You Zhou a, b, Juan Wang a, b, Hong Tang a, b, ⁎ Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 9 |
| Iconographies | 4 |
| Vidéos | 0 |
| Autres | 0 |
Highlights |
• | Serum HBcrAg presents a gradually decreasing trend from baseline to year 8, either in HBeAg-negative or HBeAg-positive patients. |
• | On-treatment HBcrAg levels are significantly lower in patients with HBeAg seroconversion than patients without HBeAg seroconversion. |
• | Baseline HBcrAg is an independent predictor of serum HBcrAg < 3 log 10 U/mL at year 8 of nucleos(t)ide analogs therapy. |
Summary |
Aim |
This study aimed to investigate long-term kinetics of serum hepatitis B core-related antigen (HBcrAg) and its correlation with serum hepatitis B surface antigen (HBsAg) in a real-world cohort of patients who had received over 8 years of nucleos(t)ide analogs(NAs) therapy.
Methods |
This was a retrospective study. All patients were recruited from our previous published study, who started therapy with NAs between 2007 and 2008. Serum HBcrAg and HBsAg levels were quantitatively measured at baseline, the sixth month and each year of follow-up, using the stored serum samples.
Results |
Among the 94 patients, serum HBcrAg presented a gradually decreasing trend from baseline to year 8, either in HBeAg-negative or HBeAg-positive patients. After 8 years of NAs treatment, 21.3% of patients achieved serum HBcrAg < 3 log 10 U/mL, and only baseline HBcrAg was an independent predictor. Additionally, good correlation of HBcrAg and HBsAg was observed at baseline, but this correlation weakened remarkably during treatment.
Conclusion |
Serum HBcrAg is decreasing gradually with the duration of antiviral therapy, and baseline HBcrAg level is an independent predictor of long-term HBcrAg below the limit of detection.
Le texte complet de cet article est disponible en PDF.Keywords : Hepatitis B, Serum hepatitis B core-related antigen, Kinetics, Nucleos(t)ide analogs therapy
Plan
Vol 43 - N° 3
P. 301-309 - juin 2019 Retour au numéro
Article précédent
- Targeting Mcl-1 inhibits survival and self-renewal of hepatocellular cancer stem-like cells
- Huapeng Zhang, Gongquan Li, Guanghui Chen, Yi Zhang, Jie Pan, Hongwei Tang, Jie Li, Wenzhi Guo, Shuijun Zhang
- Baseline HBsAg levels associated with HBsAg loss in HBeAg-negative chronic hepatitis B infection with persistently normal alanine aminotransferase
- Li Chen, Junjie Shi, Zhonghua Lu, Yun Ye, Xinbei Zhou, Youwen Tan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?